RIFASYNT

This brand name is authorized in Cyprus, Estonia, Hong Kong, Malta

Active ingredients

The drug RIFASYNT contains one active pharmaceutical ingredient (API):

1 Rifampicin
UNII VJT6J7R4TR - RIFAMPIN

Rifampicin is an active bactericidial antituberculosis drug which is particularly active against the rapidly growing extracellular organisms and also has bactericidial activity intracellularly. Rifampicin inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.

Read about Rifampicin

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
RIFASYNT Hard gelatin capsule Υπουργείο Υγείας (CY) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
J04AB02 Rifampicin J Antiinfectives for systemic use → J04 Antimycobacterials → J04A Drugs for treatment of tuberculosis → J04AB Antibiotics
Discover more medicines within J04AB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1440470
Country: HK Department of Health Drug Office Identifier(s): 22590, 22592
Country: MT Medicines Authority Identifier(s): AA032/06002

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.